A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI)

Esophagus

Volumn 11, Issue 3, 2014, Pages 183-188

  Kato, Ken ^a   Muro, Kei ^a,b   Ando, Nobutoshi ^c   Nishimaki, Tadashi ^d   Ohtsu, Atsushi ^e   Aogi, Kenjiro ^f   Aoyama, Norio ^g   Nagai, Kagami ^h   Kato, Hoichi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c TOKYO DENTAL COLLEGE   (Japan)

^d UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g KANAGAWA CANCER CENTER   (Japan)

^h TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

5 FU; Chemotherapy; Esophageal squamous cell carcinoma; Nedaplatin

Indexed keywords

EID: 84904433238     PISSN: 16129059     EISSN: 16129067     Source Type: Journal    
DOI: 10.1007/s10388-014-0427-7     Document Type: Article

References (28)

1. Cancer Statistics in Japan 2007.
2. Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22:172-6.
3. Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31:419-23. (Pubitemid 33039748)
4. Grünberger B, Raderer M, Schmidinger M, et al. Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res. 2007;27:2705-14. (Pubitemid 47227986)
5. Suzumura Y, Kato T, Ueda R, et al. Effect of treatment schedule on antitumor activity of glycolate-0,0́-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II). Anticancer Res. 1989;9:1083-8. (Pubitemid 19266360)
6. Sasaki Y, Fukuda M, Morita M, et al. Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O')-diammine platinum (II) (NSC375101D). Jpn J Cancer Res. 1990;81:196-200. (Pubitemid 20092573)
7. Takeda Y, Kasai H, Uchida N, et al. Enhanced antitumor efficacy of nedaplatin with 5-fluorouracil against human squamous carcinoma xenografts. Anticancer Res. 1999;19(5B):4059-64.
8. Ota K, Wakui A, Majima H, et al. Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II). Gan To Kagaku Ryoho. 1992;19:855-61.
9. Inuyama Y, Miyake H, Horiuchi M, et al. An early phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho. 1992;19:863-9.
10. Furuse K, Fukuoka M, Kurita Y, et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer. Gan To Kagaku Ryoho. 1992;19:879-84.
11. Kato T, Nishimura H, Yakushiji M, et al. Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Gan To Kagaku Ryoho. 1992;19:695-701.
12. Taguchi T, Wakui A, Nabeya K, et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho. 1992;19:483-8.
13. Japanese Classification of Esophageal Cancer, 10th edn. Kanehara Shuppan, 2008.
14. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216-20. (Pubitemid 27359638)
15. Ishikura S, Ohtsu A, Shirao K, et al. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG 9908). Esophagus. 2005;2:133-7. (Pubitemid 41374033)
16. Sato Y, Takayama T, Sagawa T, et al. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. Cancer Chemother Pharmacol. 2006;58:570-6. (Pubitemid 44167381)
17. Conroy T, Yataghène Y, Etienne PL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer. 2010;103:1349-55.
18. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86:1086-91. (Pubitemid 24228477)
19. Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinumbased chemotherapy. Cancer Chemother Pharmacol. 2011;67: 1265-72.
20. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16:1826-34.
21. Heath EI, Urba S, Marshall J, et al. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investig New Drugs. 2002;20:95-9. (Pubitemid 34251655)
22. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of singleagent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955-9. (Pubitemid 39004353)
23. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cis-platin- 5-fluorouracil versus cisplatin-5-fluorouracil alone in firstline metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20:1667-73.
24. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375:1030-47.
25. Stella GM, Luisetti M, Inghilleri S, et al. Targeting EGFR in non-small- cell lung cancer: lessons, experiences, strategies. Respir Med. 2012;106:173-83.
26. Sudo T, Mimori K, Nagahara H, et al. Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol. 2007;33:44-8. (Pubitemid 46131879)
27. Licitra L, Mesia R, Rivera F. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011;22:1078-87.
28. Caroli-Bosc FX, Van Laethem JL, Michel P, et al. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) ± leucovorin and biweekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. Eur J Cancer. 2001;37(15): 1828-32. (Pubitemid 32916160)